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Abstract
Alpha-fetoprotein (AFP) is a major serum protein produced during fetal development. Experimental findings suggest that
AFP has antiestrotrophic activity and that it can be developed as a therapeutic agent to treat existing estrogen-dependent
breast cancer or to prevent premalignant foci from developing into breast cancer. The antiestrotrophic activity of AFP was
reported to be localized to a peptide consisting of amino acids 447^480, a 34-mer peptide termed P447. A series of parsings
and substitutions of amino acids in the P447 sequence was intended to identify the shortest analog which retained
antiestrotrophic activity. Peptides related to P447 were generated using solid phase peptide synthesis. Several shorter
peptides, including an 8-mer called P472-2 (amino acids 472^479, peptide sequence EMTPVNPG), retained activity, whereas
peptides shorter than eight amino acid residues were inactive. The dose-related antiestrotrophic activity of AFP-derived
peptides was determined in an immature mouse uterine growth assay that measures their ability to inhibit estradiol-
stimulated uterine growth. In this assay, the maximal inhibitory activities exhibited by peptide P472-2 (49%), by peptide P447
(45%), and by intact AFP (35^45%) were comparable. The octapeptide P472-2 was also active against estradiol-stimulated
growth of T47D human breast cancer cells in culture. These data suggest that peptide P472-2 is the minimal sequence in AFP,
which retains the antiestrotrophic activity found with the full-length molecule. The synthetic nature and defined structure of
this 8-mer peptide suggest that it can be developed into a new drug which opposes the action of estrogen, perhaps including
the promotional effects of estradiol in the development of human breast cancer. ß 2000 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Alpha-fetoprotein (AFP) is a glycoprotein pro-
duced during pregnancy by the fetal yolk sac and
by fetal liver and is a major protein constituent of
fetal plasma throughout gestation [1]. It has a mo-
lecular weight of approximately 69 kDa and has 39%
primary structural homology to albumin [2]. It has
been proposed that the tertiary structure of AFP is
composed of three domains based on its disul¢de
bonding pattern [3]. In studies designed to assess
the regulation of breast cancer growth by AFP [4^
13], we have reported that full-length AFP, isolated
from a variety of sources including a human hepato-
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ma cell line (HepG-2), stopped growth of estrogen-
dependent breast cancers, but did not inhibit the
growth of estrogen-independent breast cancers
when these were growing as xenografts under the
kidney capsule of immune-de¢cient (SCID) mice
[4].
Part of our e¡ort has been directed toward ¢nding
the active site of the AFP molecule that is responsi-
Fig. 1. (A) The primary structure, domain and subdomain designation of AFP. Black circles represent the 8-mer peptide P472-2. The
8-mer peptide is the minimal sequence required for antiestrotrophic activity. (B) Energy-minimized structure of peptide P472-2. Amino
acids are labeled using three-letter code. The energy minimization calculations were done with ChemSketch program based on
CHARMM parameterization.
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ble for its ability to inhibit the growth of estrogen-
stimulated breast cancer. Molecular biology tools
were used to parse the AFP molecule into its do-
mains and subdomains (Fig. 1A). Domain III and
subdomain IIIAB were found to be active [10,11].
Synthetic peptides from the active subdomain of do-
main III were generated using solid phase peptide
synthesis, and a 34-mer peptide (amino acids 447^
480) was found to be active [14]. In this paper, we
report that an AFP-derived octapeptide comprised of
amino acids 472^479 (Fig. 1) arising from the car-
boxy-terminus of the above 34-mer peptide (amino
acids 447^480) is the minimal sequence required for
antiestrotrophic activity (Fig. 1).
2. Materials and methods
2.1. Secondary structure prediction and homology
search
Potential secondary structures of peptide P447
were predicted using Predictprotein, an internet-
based program which reportedly predicts secondary
structure of proteins and solvent accessibility at bet-
ter than 70% accuracy [15]. In addition, a sequence
homology assessment was performed using the pro-
tein data bank of Research Collaboratory for Struc-
tural Bioinformatics. Energy minimization computa-
tions were done with ChemSketch program. The
program produces energy-minimized structure based
on CHARMM parameterization [16]. Note that the
program is not a full-scale molecular mechanics en-
gine. Its design aims were to reliably reproduce rea-
sonable conformations of 3D structure.
2.2. Peptide synthesis
Peptides were synthesized using Fmoc solid phase
peptide synthesis on a Pioneer Peptide Synthesis Sys-
tem (PerSeptive Biosystem, Inc.). Brie£y, peptides
were assembled on a solid support (Fmoc^polyethyl-
ene^graft polystyrene support) from the C-terminus,
reacting the deblocked N-terminus of support-bound
amino acid with the activated C-terminus of the in-
coming amino acid to form an amide bond. Amino
acids used in the synthesis had their NK-amino group
protected by the 9-£uorenylmethoxycarbonyl (Fmoc)
group, which was removed by piperidine at the end
of each cycle in the synthesis. Side-chain protecting
groups of amino acids were Arg(Pbf), Asn(Trt),
Asp(OtBu), Gln(Trt), Glu(OtBu), His(Trt), Lys-
(tBoc), Ser(tBu), Thr(tBu), Cys(Trt), which were de-
protected by tri£uoroacetic acid (TFA) after peptide
synthesis. The carboxyl group of the amino acid was
activated with HATU [O-(7-azabenzotriazol-1-yl)-
1,1,3,3-tetramethyluronium hexa£uorophosphate]
obtained from PerSeptive Biosystems Inc. The spe-
ci¢c amino acid derivatives, supports, and reagents
used in the synthesis were purchased from PerSeptive
Biosystems Inc., Framingham, MA, USA.
Peptides were cleaved from the solid support
(polyethylene^graft polystyrene) using TFA. After
synthesis was completed, the resin was washed three
times with 100% methanol and the cleavage reaction
was initiated by incubating the resin in 10 ml TFA/
thioanisole/anisole/1,2-ethanedithiol (90:5:2:3) per
0.5 g resin for 5 h (or other appropriate conditions).
The cleavage reaction mixture was ¢ltered using a
sintered glass funnel to separate the solid resin
from the peptide solution. Filtrate volume was re-
duced to 1 ml with a gentle stream of air and the
peptides were precipitated by addition of 15 ml dry-
Fig. 1 (continued).
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ice chilled ethyl ether. The peptides were allowed to
settle for 5 min at 380‡C, and the supernatant was
aspirated. The peptides were then washed twice in
similar manner with 15 ml of ethyl ether. After three
further washes with 15 ml of 1.5:1 ethyl acetate:
diethylether (room temperature), the peptides were
dissolved in deionized water and lyophilized.
2.3. Puri¢cation of peptides
Lyophilized peptides were dissolved in deionized
water and subjected to reversed-phase chromatogra-
phy with C18 Sep-Pak Cartridges (Waters Inc.), or to
gel ¢ltration on Sephadex G-25. Subsequently, pep-
tides were lyophilized, dissolved in deionized water
and further puri¢ed using analytical or semi-prepa-
rative reversed phase HPLC.
2.4. Peptide characterization
Amino acid analysis of all peptides was performed
using the Waters AccQ-Tag amino acid analysis sys-
tem [17,18]. Additionally, peptides were analyzed by
mass spectrometry using standard K-cyano-4-hy-
droxysinnipinic acid and sinnipinic acid matrices.
2.5. Immature mouse uterine growth assay
A bioassay for antiestrotrophic activity was per-
formed according to Mizejewski et al. [19]. Swiss/
Webster female mice, 6^8 g in body weight (13^15
days old), were obtained from Taconic Farms (Ger-
mantown, NY). Mice were weighed and distributed
into treatment groups (typically ¢ve mice per group)
such that each group contained the same range of
body weight. In a typical experiment, each group
received two sequential intraperitoneal injections 1 h
apart. Test material or vehicle control for that
material was contained in the ¢rst injectant. Estrogen
or vehicle control for estrogen was contained in the
second injectant. Twenty-two hours after the second
injection, uteri were dissected, trimmed free of mes-
enteries, and immediately weighed. The uterine
weights were normalized to mouse body weights
(mg uterine weight/g of body weight) to compensate
for di¡erences in body weight among litters of the
same age. Experiments employed a minimum of ¢ve
mice per group, and the mean normalized uterine
weights and standard error for each group were cal-
culated. Percent growth inhibition in a test group
was calculated from the normalized uterine wet
weights according to Eq. 1. Groups were considered
to be signi¢cantly di¡erent at 0.05vP, employing
the non-parametric one- sided Wilcoxon sum of
ranks test.
Growth inhibition % 
Full E2 stimulation3E2 stimulation in test group
Full E2 stimulation3No E2 stimulation
U100 1
2.6. T47 cell proliferation assay
A con£uent culture of T47D human breast cancer
cells growing in culture was released from monolayer
by trypsinization (0.25% trypsin and 0.25% EDTA).
Stock T47D cells were suspended in phenol red-free
Dulbecco’s modi¢ed Eagle’s medium (DMEM) sup-
plemented with 10% dextran/charcoal-treated fetal
bovine serum (DCFBS). Cells were then seeded
into 6 well plastic tissue culture plates at a density
of 1U105 cells/well in 4 ml of medium. The plates
were incubated at 37‡C in a humidi¢ed atmosphere
containing 5% CO2. The cells were depleted of ste-
roids by replenishment of DCFBS-supplemented me-
dium every other day for 5 days. After steroid deple-
tion, estradiol (10 nM E2), vehicle, or E2 with
various concentrations of test agents were added
with medium change every other day for 9 days. At
the end of each experiment, cells were released from
monolayer by trypsinization, diluted in a 1:1 ratio of
0.1% trypan blue, and placed in a hemocytometer
and counted. Wells were set up in triplicate for
each group. Mean viable cell numbers and the stan-
dard error were calculated for each group.
3. Results
The 34-mer AFP-derived peptide described by
Mizejewski et al. [14] was synthesized. It contained
amino acids 447^480 of AFP (Fig. 1). Mass spec-
trometry analysis showed the expected molecular
weight of the peptide and amino acid analysis re-
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vealed that it had the expected amino acid composi-
tion. As shown in Fig. 2, it signi¢cantly inhibited
estrogen-stimulated growth of immature mouse ute-
rus, and its optimal dose was 1.0 Wg per mouse.
Potential secondary structures of the 34-mer AFP-
derived peptide (amino acids 447^480 in AFP) were
assessed using Predictprotein [15], which suggested
that the amino acids in sequence positions 461^471
of peptide P447 have potential to form extended
L-sheet structure, while the amino- and the car-
boxy-termini have potential to form a random coil
structure. Predictprotein predicted no potential for
K-helix structure. Peptide P447 has two cysteine res-
idues (C455, C468), which have the potential to form
intra- or inter-peptide disul¢de bonds. These obser-
vations led us to produce a number of P447 analogs
with amino acid substitutions designed to alter or
eliminate the potential L-sheet structures or to pre-
vent disul¢de formation (Table 1).
The speci¢c rationales for designing analogs of
P447 were:
1. To prevent disul¢de bond formation. Analogs in
this category included 34-mer peptides (P447-1,
P447-2, P447-3), in which substitutions for the
two cysteines were made (Table 1).
2. To reduce the L-sheet content. Analogs in this
category include two 34-mer peptides (P447-2,
P447-3), in which cysteine was substituted with
aspartate or proline, respectively (Table 1). Aspar-
tate substitution was expected to reduce potential
L-sheet structure formation and to increase the
solubility of the peptide, while proline substitution
was expected to reduce potential L-sheet structure
formation and increase random coil structure.
These substitutions also eliminated the possibility
of disul¢de bond formation as did substitution
with alanine to produce analog P447-1.
Biological activities of the peptides were evaluated
using the immature mouse uterine growth bioas-
say as described in Section 2. AFP-derived 34-mer
peptides P447, P447-1, P447-2, and P447-3 exhib-
ited signi¢cant inhibitory activity (Table 1). How-
ever, their activities were reduced after storage for
3^4 weeks (data not shown). Importantly, P447-1
is active and contains no cystine or cysteine.
Those residues are therefore not essential for anti-
estrotrophic activity, and disul¢de bond formation
is evidently not the cause of loss of that activity
during storage. In addition, substitution that
would disrupt possible L-sheet structure in pep-
tides P447-2 and P447-3 did not abolish the bio-
logical activity, which suggests that L-sheet struc-
ture might not be essential for activity. Circular
dichroism is not especially revealing for peptides
as small as these, undoubtedly because they can
access so many di¡erent conformations in solu-
tion. Similarly, secondary structure analyses of
peptides this small are usually unrevealing for
the same reason, and this is the case with these
peptides. Further, any relationship between the
solution conformation(s) of the peptides and the
conformation they may adopt when bound to the
receptor is unknown. Nevertheless, these results
suggested that the antiestrotrophic activity might
be retained by smaller analogs of the 34-mer pep-
tides.
3. Truncated forms of the 34-mer were synthesized
Table 1
Antiestrotrophic activity and sequence of AFP-derived 34-mer peptides
Test agent % Inhibition of E2-stimulated growth of
immature mouse uterus
Peptide sequence
Peptide P447 441* LSEDK LLACG EGAAD IIIGH LCIRH EMTPV NPGV
Peptide P447-1 39* LSEDK LLAAG EGAAD IIIGH LAIRH EMTPV NPGV
Peptide P447-2 45* LSEDK LLADG EGAAD IIIGH LDIRH EMTPV NPGV
Peptide P447-3 30* LSEDK LLAPG EGAAD IPIGH LPIRH EMTPV NPGV
Peptide 447 is an AFP-derived 34-mer peptide; P447-1 is an alanine-substituted 34-mer analog (C455A, C468A); P447-2 is an aspar-
tate-substituted 34-mer analog (C455D, C468D); P447-3 is a proline-substituted 34-mer analog (C455P, I463P, C468P). The optimal
inhibitory dose of peptide (1 Wg) per mouse was given by the i.p. route. The optimal stimulatory dose of E2 (0.5 Wg per mouse) was
given by the i.p. route 1 h after injection of test agent. Twenty-two hours later uteri were dissected, weighed, and compared to uterine
weights from no E2 (negative control) or E2 alone (positive control) groups.
*Signi¢cant inhibition, P6 0.05; Wilcoxon sum of ranks test.
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to identify the active site of peptide P447. Analogs
in this category included two 10-mer peptides
(P447-4, P457) and one 14-mer peptide (P467-1).
The two 10-mer peptides P447-4 and P457 were
derived from the amino-terminus and middle of
34-mer peptide P447, while a 14-mer peptide
P467-1 was derived from the carboxy-terminus
of 34-mer peptide P447. The 14-mer peptide
P467-1 exhibited signi¢cant antiestrotrophic activ-
ity while 10-mer peptides P447-4 and P457 did not
(Table 2). Therefore, the antiestrotrophic site was
thought to reside within sequence position 467^
480.
4. To identify the minimal sequence required for
antiestrotrophic activity, truncated forms of the
14-mer 467-1 were synthesized. Analogs in this
category included a 10-mer peptide (P471), a
9-mer peptide (P472-1), an 8-mer peptide (P472-
2), three 7-mer peptides (P472-3, P473, P474), and
a 5-mer peptide (P472-4). All the peptides in this
category were derived from the carboxy-terminus
of 14-mer peptide P467-1 (Table 2).
Peptide P472-2 is an 8-mer peptide from the C-
terminus of the 14-mer, and this small peptide exhib-
ited signi¢cant antiestrotrophic activity (Table 2).
However, peptides smaller than the 8-mer, P472-3
(7-mer missing the 8-mer C-terminal residue), P473
(7-mer missing N-terminal residue of the 8-mer),
P474 (7-mer missing two N-terminal residues of the
8-mer and having an additional C-terminal residue),
Table 2
Antiestrotrophic activity and sequence of AFP-derived small peptides
Test agent % Inhibition of E2-stimulated
growth of immature mouse uterus
Peptide sequence
Peptide P447 44* LSEDK LLACG EGAAD IIIGH LCIRH EMTPV NPGV
Peptide P447-4 10 LSEDK LLADG
Peptide P457 0 EGAAD IPIGH
Peptide P467-1 40* LAIRH EMTPV NPGV
Peptide P471 38* H EMTPV NPGV
Peptide 472-1 40* EMTPV NPGV
Peptide P472-2 49* EMTPV NPG
Peptide P472-3 20 EMTPV NP
Peptide P472-4 5 EMTPV
Peptide P473 0 MTPV NPG
Peptide P474 0 TPV NPGV
P447-4 is an aspartate-substituted 10-mer analog (C455D); P457 is a proline-substituted 10-mer analog (I463P); P467-1 is alanine sub-
stituted 14-mer analog (C468A); P471 is a 10-mer analog; P472-1 is a 9-mer analog; P472-2 is an 8-mer analog; P472-3 is a 7-mer
analog; P472-4 is a 5-mer analog; P473 is a 7-mer analog missing N-terminal residue of the P472-2; P474 is a 7-mer analog missing
two N-terminal residues of P472-2 and addition of C-terminal valine. The optimal inhibitory dose of peptide (1 Wg) per mouse was
given by the i.p. route. The optimal stimulatory dose of E2 (0.5 Wg per mouse) was given by the i.p. route 1 h after injection of test
agent. Twenty-two hours later uteri were dissected, weighed, and compared to no E2 (negative control) or E2 alone (positive control).
*Signi¢cant inhibition, P6 0.05; Wilcoxon sum of ranks test.
Fig. 2. Dose-dependent antiestrotrophic activity of AFP-derived
34-mer peptide P447. These results demonstrate that AFP-de-
rived 34-mer peptide signi¢cantly inhibited estrogen-stimulated
growth of immature mouse uterus, and its optimal dose was 1.0
Wg per mouse.
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and P472-1 (5-mer peptide missing three C-terminal
residues of the 8-mer) were all without signi¢cant
inhibitory activity (Table 2). These results indicated
that the 8-mer peptide (amino acids 472^479 of AFP)
is the minimal sequence from AFP that retains the
antiestrotrophic activity of the full-length molecule.
A dose^response curve of this peptide is shown in
Fig. 3. It is virtually superimposable on the dose^
response curve of the 34-mer peptide P447 (Fig. 2)
suggesting no loss of activity as a result of truncating
the larger peptide.
Interestingly, in comparing the dose^response
curves of the two peptides (Figs. 2 and 3) to that
of AFP (Fig. 4), it is apparent that the peptides are
active at a dose 100-fold lower than AFP. However,
as previously reported by our group [4,6,7], preincu-
bation of AFP with a molar excess of estradiol shifts
its dose^response curve two logs to the left (Fig. 4)
which now mimics the dose^response curve of the
peptides. We have speculated that the active site of
AFP was more accessible to its receptor in the pres-
ence of estradiol, perhaps through an estrogen-medi-
ated conformational change in AFP which alleviated
some steric hindrance in placing its active site in
apposition to the receptor [11^13]. It would appear
Fig. 4. Dose-dependent antiestrotrophic activity of intact AFP
(F) and E2-transformed AFP (b). These results demonstrate
that intact AFP and AFP/E2 (AFP preincubated with a molar
excess estradiol) are antiestrotrophic. Transformed AFP shifts
the dose^response curve two logs to the left and mimics the
dose^response curve of the peptides.
Fig. 3. Dose-dependent antiestrotrophic activity of AFP-derived
8-mer peptide P472-2. These results demonstrate that AFP-de-
rived 8-mer peptide signi¢cantly inhibited estrogen-stimulated
growth of immature mouse uterus, and its optimal dose was 1.0
Wg per mouse.
Fig. 5. The antiestrotrophic activity of octapeptide (b) and 34-
mer peptide (F) following storage. Peptides were lyophilized
and stored at 4‡C. These results show that the antiestrotrophic
activity of peptides was diminished upon prolonged storage.
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that such hindrance is not present in either the
34-mer peptide or the 8-mer peptide, and in fact
preincubation of these peptides with a molar excess
of estradiol did not alter their antiestrotrophic activ-
ity (data not shown, [14]). On a molar basis it ap-
pears that the estradiol-transformed AFP is more
active than the peptides. This may be due to di¡er-
ences in pharmacokinetics and/or active site stability.
It was hoped that the amino acid substitutions in
the 34-mer and/or its truncation to the minimal ami-
no acid sequence required for full activity (8-mer,
P472-2) would increase the storage stability of these
peptides. As shown in Fig. 5, activity of the 8-mer
peptide decays more slowly than that of the native
34-mer peptide. None of the substitutions in the 34-
mer peptide solved this storability problem. The fail-
ure to retain activity during storage is not due to any
chemical modi¢cation as assessed by mass spectrom-
etry, and is likely attributable to aggregation of these
peptides even in their lyophilized state. This aspect of
development of these peptides is still under investi-
gation.
The anti-breast cancer activity of the octapeptide
was assessed against estradiol-stimulated growth of
T47D human breast cancer cells in culture. As shown
in Fig. 6, AFP-derived octapeptide inhibited T47D
growth by 65% (similar to 34-mer peptide P447, data
not shown). Raloxifene (LY 156758) produced al-
most 100% growth inhibition of these cells in culture.
4. Discussion
The data reported herein demonstrate that an oc-
tapeptide, P472-2 (amino acids 472^479 of AFP),
possessed the antiestrotrophic activity of full-length
AFP. Festin et al. [10,11] had previously shown that
this activity was contained in the third domain of
AFP (amino acids 386^592), and Mizejewski et al.
[14] showed the activity resided in a 34-mer peptide
(amino acids 447^480) from domain III of AFP. This
8-mer peptide is a substantially truncated form of the
34-mer and yet retains signi¢cant activity. Smaller
regions within this 8-mer were without activity. A
homology search revealed a ¢ve-amino acid sequence
(EMTPV, amino acids 472^476 of AFP) that was
found in the tumor suppressor protein E-cadherin.
This 5-mer peptide was therefore synthesized and
tested, and it showed no signi¢cant antiestrotrophic
activity. The AFP-appropriate amino acids were
added to the carboxyl end of this peptide and no
signi¢cant activity was obtained until the 8-mer (ami-
no acids 472^479 of AFP) was reached. Thus the
8-mer is the minimal sequence required for antiestro-
trophic activity, and this appears to be the active site
of AFP that imparts this activity to the full-length
protein.
Full-length AFP, domain III AFP and the AFP-
derived peptides described herein lose activity during
storage. Wu et al. [20] reported that AFP tends to
form aggregates which may contribute to its loss of
activity. Lai et al. reported that peptides are prone to
chemical degradation pathways even upon storage in
the solid state [21]. Possible chemical modi¢cations
of the 8-mer peptide P472-2 might include covalent
modi¢cations such as deamination of asparagine, ox-
idation of methionine, or N-terminal pyroglutamate
formation, each of which could be detected by mass
spectrometry analysis. Mass spectrometry analysis of
the 8-mer peptide P472-2 when freshly prepared, or
Fig. 6. Growth inhibitory activity of peptide P472-2 against
T47D human breast cancer cells growing in culture. The con-
centration of estradiol (E2), peptide, and raloxifene (LY156758)
were 10 nM, 10 nM, and 100 nM respectively. For peptide and
raloxifene these were their maximal inhibitory concentrations.
These results show that AFP-derived octapeptide P472-2 inhib-
its estrogen-stimulated growth of T47D human breast cancer
cells in culture.
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after storage in the solid state for over 3 months,
indicated the expected molecular weight of 842.
This result suggested that the 8-mer peptide P472-2
was free of these chemical modi¢cations and that
chemical modi¢cation was not the cause of activity
loss during storage. In addition to chemical instabil-
ity, peptides may be prone to physical instability that
alters their biological activity [22]. Preliminary stud-
ies suggest that the 8-mer peptide and the 34-mer
AFP-derived peptides exhibited physical instability,
through aggregation. It was noted from gel ¢ltration
chromatography pro¢les that the 34-mer peptide
P447 (the parent peptide of P472-2) would readily
form dimers, trimers, and large molecular weight ag-
gregates (unpublished observation). This aggregation
process of the 34-mer peptide in the lyophilized state
resulted in a time-dependent loss of biological activ-
ity as assessed by the immature mouse uterine
growth bioassay. Preliminary data suggest that the
8-mer, like the 34-mer, forms aggregates during stor-
age in the lyophilized state. Further chemical modi-
¢cations of the peptide may be necessary to prevent
aggregation and concomitant loss of activity during
storage.
The mechanism by which AFP and the peptides
derived therefrom produce their antiestrotrophic ef-
fect is not known. Bennett et al. [4] suggested that
sequestering of estrogen by AFP is unlikely because
human AFP does not have a high-a⁄nity binding
site for estrogen. That the 8-mer retains antiestrotro-
phic activity further supports this concept because it
is highly unlikely that such a small molecule could
sequester signi¢cant amounts of estrogen. Moreover,
the inhibitory mechanism is not like that of raloxi-
fene or tamoxifen in that AFP does not block the
binding of estrogen to the estrogen receptor; nor is it
like that of letrozole because AFP does not reduce
the serum estrogen levels [4]. It is certainly di¡erent
from cytotoxic chemotherapy, because all evidence
has shown AFP to be cytostatic and non-toxic [4].
Although the mechanism of both AFP and AFP-de-
rived peptide is not yet known, when elucidated it is
likely to be novel since the more obvious processes
described above were not implicated.
AFP is found in the serum of pregnant women,
and term pregnancy reduces a woman’s future breast
cancer risk. Epidemiological studies have been per-
formed to test the hypothesis that AFP in maternal
serum (MSAFP) is the agent that reduces risk. Sev-
eral studies have examined surrogate variables that
are known to be associated with elevated serum lev-
els of AFP. It was conjectured that twin pregnancies,
in which MSAFP is double that for singleton preg-
nancies, should generate a much greater reduction of
breast cancer risk. Using data from the Cancer and
Steroid Hormones Study [23], Jacobson et al. [24]
examined the reproductive histories (parity and inci-
dence of twins) of 3918 women who were newly di-
agnosed with breast cancer and of 4097 control
women. As expected, parous women were found to
be at lower risk for breast cancer than were nullipar-
ous women. More noteworthy, those who were
mothers of twins had a further 40% reduction in
risk compared to mothers who had borne only a
singleton. Elevated MSAFP is also a characteristic
of women who are hypertensive during pregnancy
or who are bearing a fetus with an open neural
tube defect. Epidemiologic investigations have found
that in both of these problem pregnancies, the wom-
an’s subsequent breast cancer risk was reduced below
that which follows a normal pregnancy [25,26]. Re-
cently, Richardson et al. [27] have reported that the
concentration of AFP in cryogenically stored mater-
nal sera was inversely correlated to the risk of breast
cancer in these mothers 20^30 years after their preg-
nancies. These ¢ndings support the contention that
the action of AFP in maternal serum is preventing
appearance of many breast malignancies. In rats,
pregnancy reduces the incidence of N-nitroso-N-
methylurea-induced mammary tumor [28]. Sonnen-
schein et al. [29] have shown that hepatomas secret-
ing AFP resulted in inhibition of estrogen-dependent
growth of rat mammary tumors. This suggests that
AFP-derived peptides may be developed as agents
for breast cancer prevention in women. This specu-
lation is supported by the fact that full-length AFP
inhibited the estrogen-stimulated growth of estrogen
receptor-positive MCF-7 and T47 human breast can-
cer xenografts, but did not a¡ect the growth of estro-
gen receptor-negative MDA-MB-231 and BT20 hu-
man breast cancers [4]. It is noteworthy that the AFP
preparations which completely inhibited estrogen-
stimulated growth of MCF-7 human breast cancer
xenografts had 35^45% growth inhibitory activity
in the immature mouse uterine growth assay [4].
This suggests that the AFP-derived octapeptide
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P472-2, which had antiuterotropic activity in the 40^
50% range, will have a potency similar to that of
AFP against human breast cancer xenografts. Stud-
ies to con¢rm this speculation are under way.
AFP-derived octapeptide should be more readily
adapted for use in the clinic for the treatment of
estrogen receptor-positive human breast cancer than
full-length AFP. The primary structure of the 8-mer
peptide is small relative to full-length AFP (8 vs. 590
amino acids). The peptide is easier to produce. More-
over, since it is a relatively small molecule it will be
easier to design analogs. Furthermore, peptides or
analogs can be produced in large quantities in forms
that are stable on storage. Additionally, peptidomi-
metic analogs may be produced that would be e¡ec-
tive in the treatment of human breast cancer. Since
AFP is a natural product, therapeutic agents derived
from it may be less toxic than some of the therapeu-
tic agents currently used to treat breast cancer. Fur-
thermore, since almost all breast cancers initially de-
velop as estrogen receptor-positive cells and are
estrogen-driven, AFP-derived peptides may be valua-
ble for preventive as well as for therapeutic manage-
ment of human breast cancers. Thus, further devel-
opment of this 8-mer peptide appears to be indicated
because of its compelling potential to be a novel
agent for the management of breast cancer and for
the reduction of breast cancer risk in women.
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